Vicasol, 10 mg/ml 1 ml 10 pcs

Pharmacotherapeutic group: vitamin K analogue synthetic

ATX code: B02BA02

Pharmacological properties:

Pharmacodynamics

The water-soluble analogue of vitamin K (vitamin K3), promotes the synthesis of prothrombin and proconvertin, increases blood clotting by enhancing the synthesis of II, VII, IX, X clotting factors. It has a hemostatic effect (with a deficit of vitamin K occurs increased bleeding).

In the blood prothrombin (factor II) in the presence of thromboplastin and calcium ions, with the participation of proconvertin (factor VII), factors IX (Christmass-factor), X (Stuart-Prouwer factor) is converted into thrombin, which converts fibrinogen into fibrin, which is the basis of the blood clot (thrombus).

The substrate stimulates K-vitamin reductase, which activates vitamin K and ensures its participation in hepatic synthesis of K-vitamin-dependent plasma hemostatic factors. The onset of effect is 8-24 hours (after intramuscular injection).

Pharmacokinetics

After intramuscular administration it is easily and quickly absorbed. It is accumulated in small amounts in tissues. After metabolic activation it is oxidized in liver to diol form. It is excreted by kidneys and in bile mainly as metabolites. High concentrations of vitamin K in the feces are due to its synthesis by intestinal microflora.